What is Losartan 50/25 HCTZ (Hydrochlorothiazide)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Losartan 50/25 HCTZ: Medication Identification

Losartan 50/25 HCTZ is a fixed-dose combination antihypertensive medication containing 50 mg of losartan (an angiotensin II receptor blocker/ARB) and 25 mg of hydrochlorothiazide (a thiazide diuretic). 1

Medication Components

  • Losartan 50 mg: An angiotensin II receptor antagonist (ARB) that blocks the vasoconstrictive and aldosterone-secreting effects of angiotensin II 2

  • Hydrochlorothiazide (HCTZ) 25 mg: A thiazide-type diuretic with the chemical name 6-Chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1-dioxide, molecular formula C7H8ClN3O4S2 3

Clinical Indications

This combination is FDA-approved for:

  • Treatment of hypertension, including as initial therapy in severe hypertension 4
  • Stroke risk reduction in patients with hypertension and left ventricular hypertrophy 4

Available Formulations

The standard fixed-dose combinations of losartan/HCTZ available are:

  • Losartan 50 mg/HCTZ 12.5 mg 1
  • Losartan 100 mg/HCTZ 25 mg 1

Note: The "50/25" formulation you're asking about appears to refer to losartan 50 mg with HCTZ 25 mg, which is not a standard FDA-approved fixed-dose combination. 1 The standard combinations are 50/12.5 mg or 100/25 mg. If a patient requires losartan 50 mg with HCTZ 25 mg, this would typically be prescribed as separate tablets rather than a fixed combination.

Antihypertensive Efficacy

  • Losartan 100 mg/HCTZ 25 mg produces mean trough blood pressure reductions of approximately 17.5/9 mmHg in patients with moderate-to-severe hypertension, with response rates of 86.7% 5

  • Losartan 50 mg/HCTZ 12.5 mg produces mean trough blood pressure reductions of approximately 15.2/8 mmHg, with response rates of 78.9% 5

  • The addition of HCTZ 12.5 mg or 25 mg to losartan 50 mg produces effective blood pressure control in 71% and 83% of patients, respectively, who only partially responded to losartan monotherapy 6

Safety Profile

  • The combination is well-tolerated with adverse event rates similar to placebo (34.7% for losartan 100/HCTZ 25 vs 32.6% for placebo) 5

  • Drug-related adverse events occur in approximately 7-11% of patients across all treatment groups 5

  • Common adverse events include dizziness (3%), upper respiratory infection (8%), nasal congestion (2%), and back pain (2%) 2

  • Unlike ACE inhibitors, losartan has a significantly lower incidence of persistent dry cough (17-29% vs 62-69% with lisinopril) 2

Related Questions

Is it appropriate to take losartan (angiotensin II receptor blocker) combined with hydrochlorothiazide (thiazide diuretic) at night?
Is it safe for a post‑open‑heart surgery patient who is currently taking only carvedilol (Coreg) to add losartan plus hydrochlorothiazide (HCTZ) as a cost‑effective alternative to amlodipine (Norvasc) or sacubitril/valsartan (Entresto)?
What are the immediate management steps for a patient who developed symptomatic hypotension after increasing her losartan (angiotensin receptor blocker) and hydrochlorothiazide (thiazide diuretic) combination from 50 mg/12.5 mg to 100 mg/25 mg?
What is the recommended dosing for Losartan (Angiotensin II Receptor Antagonist) HCTZ (Hydrochlorothiazide)?
What is the equivalent losartan (Angiotensin II Receptor Antagonist) dosage for a patient taking Hydrochlorothiazide (HCTZ) 12.5mg?
Can Hydrochlorothiazide (HCTZ) increase cholesterol and blood sugar levels?
What antihypertensives to start in a patient post Endovascular Abdominal Aortic Aneurysm (AAA) repair?
Can hydralazine be given for acutely elevated blood pressure in a patient with end-stage kidney disease (ESKD)?
Can labetalol be given for acutely elevated blood pressure in a patient with end-stage kidney disease (Impaired renal function)?
What are the post-procedure care instructions for a patient after an angiogram?
What is the possible explanation for a patient with septic shock, chronic kidney disease on renal replacement therapy (RRT), and K. pneumoniae infection, who has episodes of vomiting with bilious output and now has bowel movements with the same consistency as the output from their nasogastric tube (NGT)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.